Myomo pre-announces Q2 revenue $3.4-3.6M, up 10-16% YoY; record pipeline adds

MYOMO, INC.

2022-Q2 EPS reported -$0.83 revenue$7,545,501

Preliminary Q2 2022 revenue $3.4–$3.6M, up 10–16% vs Q2 2021; all product revenue.
Added >400 prospective MyoPro patients in Q2, a quarterly record; cost per pipeline add decreased.
Second JV license fee payment from China partner delayed due to COVID-19 banking/government backlog.
Participated in CMS public hearing for Benefit Category Determination to reclassify MyoPro as custom-fabricated brace.
Full Q2 results and conference call scheduled for August 3, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.